Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.66 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.66 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CD69 | Q07108 | 1/20 | 0.50 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | AMY2A | P04746 | 2/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16298821 | 1.00 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30527825 | 1.00 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL29532287 | 0.96 | LGALS3 (0.61) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30267118 | 0.96 | LGALS3 (0.63) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL26491880 | 0.96 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL13577686 | 0.96 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL13855946 | 0.96 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30185411 | 0.96 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL5525281 | 0.96 | LGALS3 (0.68) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL6816305 | 0.96 | LGALS3 (0.68) | LGALS3LGALS8LGALS4MAPK1CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | claimed |
| US-20230277607-A1 | Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof | ACARYON GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-20260004881-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING PROTEINS | NAUTILUS SUBSIDIARY INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | disclosed |
| US-20230277607-A1 | Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof | ACARYON GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260004881-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING PROTEINS | PTMS, SRMS, CHAMP1 | LGALS3 1388/4885LGALS8 1371/4885LGALS4 1259/4885 |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | SGMS1, UGCG, SGMS2 | LGALS3 391/4885LGALS8 634/4885LGALS4 285/4885 |
| US-20230277607-A1 | Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof | UGCG, CERT1, SGMS2 | LGALS3 225/4885LGALS8 285/4885LGALS4 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.